An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
出版年份 2021 全文链接
标题
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade
作者
关键词
IL-21, Human serum albumin, Half-life extension, PD-1 blockade, TIGIT blockade
出版物
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 101, Issue -, Pages 108307
出版商
Elsevier BV
发表日期
2021-11-02
DOI
10.1016/j.intimp.2021.108307
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
- (2020) Ghasem Rahimi Kalateh Shah Mohammad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Antibody engineers seek optimal drug targeting TIGIT checkpoint
- (2020) Elie Dolgin NATURE BIOTECHNOLOGY
- Toripalimab: First Global Approval
- (2019) Susan J. Keam DRUGS
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
- (2017) Zachary B. Davis et al. SEMINARS IN IMMUNOLOGY
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
- (2017) Katherine E. Lewis et al. OncoImmunology
- Nanobodies as therapeutics: big opportunities for small antibodies
- (2016) Sophie Steeland et al. DRUG DISCOVERY TODAY
- Formulation and Stability of Cytokine Therapeutics
- (2015) Tiina Lipiäinen et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis
- (2015) Veronica De Simone et al. Oncotarget
- IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
- (2015) Michela Croce et al. Journal of Immunology Research
- Bioactive Albumin-Based Carriers for Tumour Chemotherapy
- (2014) Yasser Shahzad et al. CURRENT CANCER DRUG TARGETS
- Albumin and its application in drug delivery
- (2014) Darrell Sleep Expert Opinion on Drug Delivery
- Interleukin-21: a double-edged sword with therapeutic potential
- (2014) Rosanne Spolski et al. NATURE REVIEWS DRUG DISCOVERY
- Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
- (2014) Shailender Bhatia et al. Journal for ImmunoTherapy of Cancer
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Preclinical Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Interleukin-21 in Cynomolgus Macaques (Macaca fascicularis)
- (2012) Kimberly S. Waggie et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- HDX Workbench: Software for the Analysis of H/D Exchange MS Data
- (2012) Bruce D. Pascal et al. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
- Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma
- (2012) XIU-CHENG PAN et al. Oncology Letters
- Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
- (2010) Mehmood H Hashmi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Lessons from the Crystallographic Analysis of Small Molecule Binding to Human Serum Albumin
- (2009) Stephen Curry Drug Metabolism and Pharmacokinetics
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma
- (2008) John A. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search